BLSI vs. RGEN
Wednesday April 15, 2:25 pm Eastern Time
Company Press Release
SOURCE: Repligen Corporation
Repligen Receives Phase 2 SBIR Grant from the National Cancer Institute
Research Targets Testing of Small Molecule Inhibitors of Angiogenesis
NEEDHAM, Mass., April 15 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) announced today that it was awarded a $750,000 Phase 2 SBIR grant from the National Cancer Institute (NCI) to support the development of small molecule inhibitors of angiogenesis or new blood vessel growth. Angiogenesis is a process essential for the growth of solid tumors and has also been implicated in several ocular diseases including macular degeneration and diabetic retinopathy.
Repligen has identified small molecule inhibitors of two growth factors important for tumor angiogenesis. This grant will support chemical analoging of lead compounds to improve their potency and continued preclinical investigation of the action of these inhibitors. Preclinical models will be carried out at Repligen and through a collaboration with the Lombardi Cancer Center in Washington, D.C. under the direction of Dr. Marc Lippman.
''NCI has identified the inhibition of angiogenesis as a promising target for the development of new therapies for cancer,'' said Walter C. Herlihy, Ph.D., President and CEO of Repligen. ''This award represents an important endorsement of our approach to this significant problem.''
''Repligen has identified a novel approach to inhibiting angiogenesis with a small molecule,'' said Dr. Marc Lippman, Director of the Lombardi Cancer Center. ''Success in this collaboration could have broad application in cancer therapy.''
Repligen develops combinatorial chemical synthesis and high throughput screening technologies for the accelerated discovery of new pharmaceuticals capable of blocking important protein-carbohydrate and protein-protein interactions. Its corporate headquarters are located at 117 Fourth Avenue, Needham, MA 02194. Additional information may be requested via e-mail to investors@repligen.com or from www.repligen.com.
This press release contains forward-looking statements based on current management expectations. There are certain key factors which could cause future results to differ materially from those anticipated by management. Such factors include, but are not limited to: the Company's ability to continue to establish collaborative arrangements with third parties; the Company's ability to maintain financial stability; the technical risks associated with development of new products; the fact that there can be no assurances that patents relating to the Company's potential products will afford adequate protection to the Company, the risks of technological change and competition, and the competitive environment of the biotechnology and pharmaceutical industries. These factors are more fully discussed in the Company's periodic filings with the Securities and Exchange Commission.
SOURCE: Repligen Corporation |
